S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The “Perfect Storm” for Gold (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
1970’s computer coder issues shocking A.I. warning (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden’s $374B Giveaway Into This Sector (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The “Perfect Storm” for Gold (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
1970’s computer coder issues shocking A.I. warning (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden’s $374B Giveaway Into This Sector (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The “Perfect Storm” for Gold (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
1970’s computer coder issues shocking A.I. warning (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden’s $374B Giveaway Into This Sector (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The “Perfect Storm” for Gold (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
1970’s computer coder issues shocking A.I. warning (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Biden’s $374B Giveaway Into This Sector (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:BVXV

BiondVax Pharmaceuticals (BVXV) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free BVXV Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$1.26
▼
$1.59
52-Week Range
N/A
Volume
23,000 shs
Average Volume
127,289 shs
Market Capitalization
$2.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
BVXV stock logo

About BiondVax Pharmaceuticals Stock (NASDAQ:BVXV)

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

BVXV Stock News Headlines

March 23, 2024 | seekingalpha.com
SCNI Scinai Immunotherapeutics Ltd.
October 4, 2023 | finance.yahoo.com
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
April 18, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
September 19, 2023 | finance.yahoo.com
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
September 15, 2023 | finance.yahoo.com
Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
September 13, 2023 | finance.yahoo.com
Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
September 11, 2023 | finance.yahoo.com
Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
September 6, 2023 | financialpost.com
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
April 18, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
August 11, 2023 | finanznachrichten.de
BiondVax Pharmaceuticals Ltd.: BiondVax Reports Second Quarter Financial Results and Provides Business Update
August 11, 2023 | finance.yahoo.com
BiondVax Reports Second Quarter Financial Results and Provides Business Update
August 2, 2023 | finanznachrichten.de
BiondVax Pharmaceuticals Ltd.: Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
August 1, 2023 | finance.yahoo.com
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
July 28, 2023 | theglobeandmail.com
BiondVax (NASDAQ: BVXV) Leveraging NanoAb Pipeline to Target Large Markets
July 11, 2023 | finance.yahoo.com
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.
July 6, 2023 | finance.yahoo.com
BVXV - BiondVax Pharmaceuticals Ltd.
June 5, 2023 | finance.yahoo.com
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
May 30, 2023 | finance.yahoo.com
BVXV: Developing anti-IL-17 NanoAb
May 15, 2023 | finanznachrichten.de
BiondVax Pharmaceuticals Ltd.: BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023 | msn.com
Biondvax Pharmaceuticals GAAP EPS of $0.00 beats by $0.73
May 15, 2023 | finance.yahoo.com
BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
April 20, 2023 | theglobeandmail.com
BiondVax Pharmaceuticals (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team
April 18, 2023 | finanznachrichten.de
BiondVax Pharmaceuticals Ltd.: BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
April 4, 2023 | marketwatch.com
BioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies
March 26, 2023 | marketwatch.com
BioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants
March 16, 2023 | finance.yahoo.com
BiondVax to Present at BIO-Europe Spring
March 6, 2023 | finance.yahoo.com
IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman
See More Headlines
Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2022
Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BVXV
CUSIP
N/A
CIK
1611747
Web
www.biondvax.com
Phone
9723029302529
Fax
972-8930-2531
Employees
33
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,800,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-346.36%
Return on Assets
-29.52%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.12
Quick Ratio
4.12

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.81) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,870,000
Free Float
1,755,000
Market Cap
$2.54 million
Optionable
Not Optionable
Beta
2.37
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Amir Reichman M.B.A. (Age 47)
    M.Sc., CEO & Director
    Comp: $562.5k
  • Mr. Elad Mark B.Sc. (Age 41)
    Eng., M.B.A., Chief Operating Officer
    Comp: $277.02k
  • Dr. Tamar Ben-Yedidia Ph.D. (Age 59)
    Chief Science Officer
    Comp: $314.92k
  • Mr. Uri Ben-Or CPA (Age 53)
    CPA, M.B.A., MBA, Chief Financial Officer
  • Mr. Joshua E. Phillipson B.Sc.
    M.B.A., Director of Communications & Investor Relations
  • Ms. Moran Ahdout Fruchter L.L.B.
    Chief of Staff
  • Ms. Dalit Weinstein Fischer
    VP and Head of Technical R&D

Key Competitors

View All Competitors

BVXV Stock Analysis - Frequently Asked Questions

How were BiondVax Pharmaceuticals' earnings last quarter?

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) announced its quarterly earnings data on Monday, March, 28th. The company reported ($2.70) earnings per share for the quarter, missing the consensus estimate of ($0.90) by $1.80.

When did BiondVax Pharmaceuticals' stock split?

BiondVax Pharmaceuticals's stock reverse split on the morning of Friday, November 25th 2022. The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of BiondVax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

When did BiondVax Pharmaceuticals IPO?

BiondVax Pharmaceuticals (BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at a price of $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

This page (NASDAQ:BVXV) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
SHOCKING Crypto Leak…
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Top 5 AI Stocks to Buy for 2024
Market Moving Trends